Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development.
2-deoxy-D-glucose
GAO-3-02
JNJ-40411813
NBI-921352
NTX-001
XEN1101
XEN496
antiepileptic drugs
drugs development
epilepsy
sec-butylpropylacetamide
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
12
08
2020
revised:
20
09
2020
accepted:
21
09
2020
pubmed:
16
11
2020
medline:
19
12
2020
entrez:
15
11
2020
Statut:
ppublish
Résumé
Since 1992, the Eilat Conferences have provided a forum for all stakeholders in the epilepsy community to appraise the latest data on new antiepileptic drugs and emergency seizure treatments, including, in recent years, updates on progress with the development of novel monitoring and therapeutic devices. Because of the COVID-19 pandemic, the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV) was held as a fully virtual conference on July 27-30, 2020 for the sessions on drugs and on August 3, 2020 for the sessions on devices, and was attended during the 5 days by >500 participants from 63 countries. This progress report summarizes key preclinical and initial (phase 1) clinical data on eight investigational treatments that are currently in early development, including 2-deoxy-D-glucose, GAO-3-02, JNJ-40411813, NBI-921352, NTX-001, sec-butylpropylacetamide, XEN1101, and XEN496. This report provides an overview of current scenarios in the area of treatment discovery and development. The information presented illustrates a variety of innovative strategies, including exploration of compounds with novel mechanisms of action, transplantation of interneurons into epileptogenic brain regions, and the targeting of rare, previously neglected syndromes.
Substances chimiques
Anticonvulsants
0
Types de publication
Congress
Langues
eng
Sous-ensembles de citation
IM
Pagination
2340-2364Informations de copyright
© 2020 International League Against Epilepsy.
Références
Perucca E, Brodie M, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19:544-56.
Bialer M, Johannessen S, Koepp M, Levy R, Perucca E, Perucca P, et al. Progress report on new antiepileptic drugs: a summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in more advanced clinical development. Epilepsia. 2020;61:2365-2385.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. Progress report on new antiepileptic drugs: a summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia. 2018;59:1842-66.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. Progress report on new antiepileptic drugs: a summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia. 2018;59:1811-41.
Boada CM, French JA, Dumanis SB. Proceedings of the 15th Antiepileptic Drug and Device Trials meeting: state of the science. Epilepsy Behav. 2020;111:107189.
French JA, Perucca E. Time to start calling things by their own names? The case for antiseizure medicines. Epilepsy Curr. 2020;20:69-72.
Garriga-Canut M, Schoenike B, Qazi R, Bergendahl K, Daley TJ, Pfender RM, et al. 2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci. 2006;9:1382-7.
Stafstrom CE, Ockuly JC, Murphree L, Valley MT, Roopra A, Sutula TP. Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models. Ann Neurol. 2009;65:435-47.
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia. 2017;58:181-221.
Yang H, Guo R, Wu J, Peng Y, Xie D, Zheng W, et al. The antiepileptic effect of the glycolytic inhibitor 2-deoxy-D-glucose is mediated by upregulation of K(ATP) channel subunits Kir6.1 and Kir6.2. Neurochem Res. 2013;38:677-85.
Lian XY, Khan FA, Stringer JL. Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats. J Neurosci. 2007;27:12007-11.
Ding Y, Wang S, Zhang M-M, Guo YI, Yang YI, Weng S-Q, et al. Fructose-1,6-diphosphate inhibits seizure acquisition in fast hippocampal kindling. Neurosci Lett. 2010;477:33-6.
Langberg T, Dashek R, Mulvey B, Miller KA, Osting S, Stafstrom CE, et al. Distinct behavioral phenotypes in novel "fast" kindling-susceptible and "slow" kindling-resistant rat strains selected by stimulation of the hippocampal perforant path. Neurobiol Dis. 2016;85:122-9.
Sutula T, Kotloski R, Rutecki P.Brief treatment with 2DG reduces post-traumatic epilepsy with frequent focal and generalized seizures after CCI-induced TBI in unique “fast” kindling-susceptible PPKS rats. Program No. 050.27. 2019 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, October 19-23, 2019. Available at: https://www.sfn.org/meetings/neuroscience-2019. Accessed July 8, 2020.
Pan YZ, Sutula TP, Rutecki PA. 2-Deoxy-d-glucose reduces epileptiform activity by presynaptic mechanisms. J Neurophysiol. 2019;121:1092-101.
Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate. 2010;70:1388-94.
Kim HY, Spector AA. N-Docosahexaenoylethanolamine: a neurotrophic and neuroprotective metabolite of docosahexaenoic acid. Mol Aspects Med. 2018;64:34-44.
Loscher W. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Res. 2016;126:157-84.
Fares RP, Belmeguenai A, Sanchez PE, Kouchi HY, Bodennec J, Morales A, et al. Standardized environmental enrichment supports enhanced brain plasticity in healthy rats and prevents cognitive impairment in epileptic rats. PLoS One. 2013;8:e53888.
Huang BX, Hu X, Kwon H-S, Fu C, Lee J-W, Southall N, et al. Synaptamide activates the adhesion GPCR GPR110 (ADGRF1) through GAIN domain binding. Commun Biol. 2020;3:109.
Sonti S, Duclos RI Jr, Tolia M, Gatley SJ. N-Docosahexaenoylethanolamine (synaptamide): carbon-14 radiolabeling and metabolic studies. Chem Phys Lipids. 2018;210:90-7.
Park T, Chen H, Kim HY. GPR110 (ADGRF1) mediates anti-inflammatory effects of N-docosahexaenoylethanolamine. J Neuroinflammation. 2019;16:225.
Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31-9.
Ohishi H, Shigemoto R, Nakanishi S, Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience. 1993;53:1009-18.
Metcalf CS, Klein BD, Smith MD, Ceusters M, Lavreysen H, Pype S, et al. Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model. Epilepsia. 2018;59:724-35.
Metcalf CS, Klein BD, Smith MD, Pruess T, Ceusters M, Lavreysen H, et al. Efficacy of mGlu2-positive allosteric modulators alone and in combination with levetiracetam in the mouse 6 Hz model of psychomotor seizures. Epilepsia. 2017;58:484-93.
Leclercq K, Kaminski RM. Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model. Epilepsia. 2015;56:310-8.
Kent JM, Daly E, Kezic I, Lane R, Lim P, De Smedt H, et al. Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;67:66-73.
Molosh AI, Dustrude ET, Lukkes JL, Fitz SD, Caliman IF, Abreu ARR, et al. Panic results in unique molecular and network changes in the amygdala that facilitate fear responses. Mol Psychiatry. 2020;25:442-60.
Gataullina S, Dulac O. From genotype to phenotype in Dravet disease. Seizure. 2017;44:58-64.
Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci. 2006;9:1142-9.
Hu W, Tian C, Li T, Yang M, Hou H, Shu Y. Distinct contributions of Na(v)1.6 and Na(v)1.2 in action potential initiation and backpropagation. Nat Neurosci. 2009;12:996-1002.
Meisler MH, Helman G, Hammer MF, Fureman BE, Gaillard WD, Goldin AL, et al. SCN8A encephalopathy: research progress and prospects. Epilepsia. 2016;57:1027-35.
Chohan MO, Moore H. Interneuron progenitor transplantation to treat CNS dysfunction. Front Neural Circuits. 2016;10:64.
Hofmann G, Balgooyen L, Mattis J, Deisseroth K, Buckmaster PS. Hilar somatostatin interneuron loss reduces dentate gyrus inhibition in a mouse model of temporal lobe epilepsy. Epilepsia. 2016;57:977-83.
Krook-Magnuson E, Armstrong C, Oijala M, Soltesz I. On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat Commun. 2013;4:1376.
Loscher W, Gernert M, Heinemann U. Cell and gene therapies in epilepsy-promising avenues or blind alleys? Trends Neurosci. 2008;31:62-73.
Baraban SC, Southwell DG, Estrada RC, Jones DL, Sebe JY, Alfaro-Cervello C, et al. Reduction of seizures by transplantation of cortical GABAergic interneuron precursors into Kv1.1 mutant mice. Proc Natl Acad Sci U S A. 2009;106:15472-7.
Casalia ML, Howard MA, Baraban SC. Persistent seizure control in epileptic mice transplanted with gamma-aminobutyric acid progenitors. Ann Neurol. 2017;82:530-42.
Hunt RF, Girskis KM, Rubenstein JL, Alvarez-Buylla A, Baraban SC. GABA progenitors grafted into the adult epileptic brain control seizures and abnormal behavior. Nat Neurosci. 2013;16:692-7.
Henderson KW, Gupta J, Tagliatela S, Litvina E, Zheng X, Van Zandt MA, et al. Long-term seizure suppression and optogenetic analyses of synaptic connectivity in epileptic mice with hippocampal grafts of GABAergic interneurons. J Neurosci. 2014;34:13492-504.
Waldau B, Hattiangady B, Kuruba R, Shetty AK. Medial ganglionic eminence-derived neural stem cell grafts ease spontaneous seizures and restore GDNF expression in a rat model of chronic temporal lobe epilepsy. Stem Cells. 2010;28:1153-64.
Cunningham M, Cho J-H, Leung A, Savvidis G, Ahn S, Moon M, et al. hPSC-derived maturing GABAergic interneurons ameliorate seizures and abnormal behavior in epileptic mice. Cell Stem Cell. 2014;15:559-73.
Upadhya D, Hattiangady B, Castro OW, Shuai B, Kodali M, Attaluri S, et al. Human induced pluripotent stem cell-derived MGE cell grafting after status epilepticus attenuates chronic epilepsy and comorbidities via synaptic integration. Proc Natl Acad Sci U S A. 2019;116:287-96.
Broeer S, Parekh M, Fuentealba L, Spatazza J, Blankenberger W, Leedy J, et al. Transplantation of human interneurons is effective in reducing focal and generalized seizures in two mouse models of temporal lobe epilepsy. Program No. 445.06. 2019 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, October 19-23, 2019. Available at: https://www.sfn.org/meetings/neuroscience-2019/abstracts. Accessed February 24, 2020.
Duveau V, Pouyatos B, Bressand K, Bouyssières C, Chabrol T, Roche Y, et al. Differential effects of antiepileptic drugs on focal seizures in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy. CNS Neurosci Ther. 2016;22:497-506.
Shekh-Ahmad T, Hen N, McDonough JH, Yagen B, Bialer M. Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia. 2013;54(Suppl 6):99-102.
Hen N, Shekh-Ahmad T, Yagen B, McDonough JH, Finnell RH, Wlodarczyk B, et al. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. J Med Chem. 2013;56:6467-77.
Pouliot W, Bialer M, Hen N, Shekh-Ahmad T, Kaufmann D, Yagen B, et al. A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience. 2013;231:145-56.
Shekh-Ahmad T, Mawasi H, McDonough JH, Yagen B, Bialer M. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav. 2015;49:298-302.
White HS, Alex AB, Pollock A, Hen N, Shekh-Ahmad T, Wilcox KS, et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia. 2012;53:134-46.
Bibi D, Bialer M. Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-a CNS-active stereoisomer of SPD. Epilepsia. 2020;61:149-56.
Haines KM, Matson LM, Dunn EN, Ardinger CE, Lee-Stubbs R, Bibi D, et al. Comparative efficacy of valnoctamide and sec-butylpropylacetamide (SPD) in terminating nerve agent-induced seizures in pediatric rats. Epilepsia. 2019;60:315-21.
Bar-Klein G, Swissa E, Kamintsky L, Shekh-Ahmad T, Saar-Ashkenazy R, Hubary Y, et al. sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. Epilepsia. 2014;55:1953-8.
Zolkowska D, Bialer M, Rogawski M.Effects of valproic acid derivatives valnoctamide and sec-butylpropylacetamide on tetramethylene-disulfotetramine-induced status epilepticus in mice. Annual Meeting of the American Epilepsy Society; December 1-7, 2017; Washington, DC. Abstract 2.269. Available at: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/349403. Accessed January 30, 2018.
Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov. 2002;1:753-68.
Loscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991;8:79-94.
Kobayashi E, Hishikawa S, Teratani T, Lefor AT. The pig as a model for translational research: overview of porcine animal models at Jichi Medical University. Transplant Res. 2012;1:8.
Premoli I, Rossini PG, Goldberg PY, Posadas K, Green L, Yogo N, et al. TMS as a pharmacodynamic indicator of cortical activity of a novel anti-epileptic drug, XEN1101. Ann Clin Transl Neurol. 2019;6:2164-74.
Millichap JJ, Park KL, Tsuchida T, Ben-Zeev B, Carmant L, Flamini R, et al. KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol Genet. 2016;2:e96.
Kuersten M, Tacke M, Gerstl L, Hoelz H, Stulpnagel CV, Borggraefe I. Antiepileptic therapy approaches in KCNQ2 related epilepsy: a systematic review. Eur J Med Genet. 2020;63:103628.
Olson H, Kelly M, Rosen-Sheidley B, Pearl P, Poduri A.Precision treatment of KCNQ2 encephalopathy with ezogabine. American Epilepsy Society Annual Meeting 2017; December 1-5, 2017; Washington DC. Abstract 3.176. Available at: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/349819. Accessed February 21, 2020.
Ihara Y, Tomonoh Y, Deshimaru M, Zhang B, Uchida T, Ishii A, et al. Retigabine, a Kv7.2/Kv7.3-channel opener, attenuates drug-induced seizures in knock-in mice harboring Kcnq2 mutations. PLoS One. 2016;11:e0150095.
Maljevic S, Wuttke TV, Lerche H. Nervous system KV7 disorders: breakdown of a subthreshold brake. J Physiol. 2008;586:1791-801.
Watanabe H, Nagata E, Kosakai A, Nakamura M, Yokoyama M, Tanaka K, et al. Disruption of the epilepsy KCNQ2 gene results in neural hyperexcitability. J Neurochem. 2000;75:28-33.
GlaxoSmithKline. Highlights of prescribing information.POTIGA (ezogabine). 2016 revision. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022345s011lbl.pdf. Accessed February 21, 2020.
Australian Government. Department of Health, Therapeutic Goods Administration. Australian public assessment report for retigabine. October 2013. Available at: https://www.tga.gov.au/sites/default/files/auspar-retigabine-131017.pdf. Accessed March 3, 2020.
Center for Drug Evaluation and Research. Application Number: 022345Orig1s000. Pharmacology Reviews. 2011. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000PharmR.pdf. Accessed February 21, 2020.
Tompson DJ, Crean CS. Clinical pharmacokinetics of retigabine/ezogabine. Curr Clin Pharmacol. 2013;8:319-31.
Porter RJ, Burdette DE, Gil-Nagel A, Hall ST, White R, Shaikh S, et al. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials. Epilepsy Res. 2012;101:103-12.
Brickel N, Hewett K, Rayner K, McDonald S, De'Ath J, Daniluk J, et al. Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events. Epilepsy Behav. 2020;102:106580.
Dmytriyeva O, Belmeguenai A, Bezin L, Soud K, Drucker Woldbye DP, Gøtzsche CR, et al. Short erythropoietin-derived peptide enhances memory, improves long-term potentiation, and counteracts amyloid beta-induced pathology. Neurobiol Aging. 2019;81:88-101.